

**United Global Healthcare Fund**  
大華全球保健基金



Portfolios Factsheet

**Fund Objective**

The investment objective of the Fund is to achieve long term capital growth by investing in securities issued by companies principally involved in the development, production or distribution of products, equipment and/or services related to healthcare, in any part of the world. Such investments would include investing in sub-sectors of the healthcare industry such as medical products, health services, major pharmaceuticals, specialty major pharmaceuticals, and specialty pharmaceuticals.

**Fund Details**


LAUNCH DATE	July 2000
FUND SIZE	S\$50.61 million
NAV PRICE	S\$2.244 (as at 30 Apr 13)
SUBSCRIPTION	Cash & SRS
INITIAL INVESTMENT	S\$1,000
SUB INVESTMENT	S\$500
MANAGEMENT FEE	1.75% p.a.
SUBSCRIPTION FEE	5% (Cash, SRS)
MINIMUM RSP	S\$100/month, S\$500/quarter
TRUSTEE	HSBC Institutional Trust
ISIN CODE	SG9999001176
BLOOMBERG CODE	UNIGHCI SP

**Top 10 Holdings (As at 30 Apr 2013)**


- Forest Laboratories Inc
- Merck N Co
- Shionogi & Company
- UnitedHealth Grp
- Alkermes Plc
- UCB (E)
- Amgen Inc
- Walgreen Company
- Boston Scientific Corp
- NPS Pharmaceuticals Inc

**Asset Allocation (As at 30 Apr 2013)**

**By Country**




**By Sector**



**Performance**

21st August 00 To 30th April 13, Performance Based in Singapore Dollar.



\*The above chart reflects performance from the first month end of the Fund. ^5% sales charge applied.

Benchmark (BM) : MSCI ACWI Healthcare.

Perf	NAV	NAV^	BM
1 month	2.00%	-3.10%	3.28%
3 months	10.32%	4.81%	10.24%
6 months	21.43%	15.36%	21.17%
1 year	26.21%	19.90%	28.74%
3 years	10.94%	9.06%	12.73%
5 years	7.62%	6.52%	7.69%
10 years	7.86%	7.31%	4.53%
Since Incept	7.00%	6.57%	2.39%

Source: Lipper, a Thomson Reuters Company • Performance as at 30 Apr 13, SGD basis, with dividends and distributions reinvested, if any. • Performance figures for 1 mth till 1 yr show the % change, while those exceeding 1 yr show the average annual compounded return.

**Fund Awards**

The Edge-Lipper SG UT Fund Awards 13, 12, 11, 10, 09, 08, 04, 03  
SG S&P Inv. Fund Awards 06, 05, 04, 02  
SG Inv. Fund Awards 01  
S&P Fund Awards Singapore 07

**Contact Details**

Hotline (24-hour): 1800 22 22 228  
Website: uobam.com.sg

**IMPORTANT NOTICE AND DISCLAIMERS**

A prospectus for the fund(s) (the "Fund(s)") may be obtained from the Manager or any of its appointed distributors. Investors should read the prospectus before deciding whether to subscribe for or purchase units in the Fund(s) ("Units"). All applications for Units must be made on application forms accompanying the prospectus or otherwise as described in the prospectus. **Past performance of the Fund(s) or the Manager and any prediction, projection or forecast on the economy or markets are not necessarily indicative of the future or likely performance of the Fund(s) or the Manager.** Any extraordinary performance may be due to exceptional circumstances which may not be sustainable. The value of Units and any income from the Fund(s) may fall as well as rise. The above information is strictly for general information only and must not be construed as an offer or solicitation to deal in Units, nor a recommendation to invest in any company mentioned herein. Investments in unit trusts are not obligations of, deposits in, or guaranteed or insured by UOB, UOBAM, or any affiliates or distributors. The Fund may use or invest in financial derivative instruments and you should be aware of the risks associated with investments in financial derivative instruments which are described in the Fund's prospectus. An investment in unit trusts is subject to investment risks and foreign exchange risks, including the possible loss of the principal amount invested. Investors may wish to seek advice from a financial adviser before making a commitment to invest in Units. In the event an investor chooses not to seek advice from a financial adviser, the investor should consider carefully whether the Fund(s) is/are suitable for him.